INSUBCONTINENT EXCLUSIVE:
Shares of Morepen Labs settled 2.62 percent greater at Rs 68.45 each on the BSE.Morepen Laboratories reported a net revenue of Rs 30.47
crore on a consolidated basis in the April-June of the fiscal year 2021-22, compared to Rs 19.37 crore in the corresponding quarter last
year, marking a development of 57 percent year-on-year
The leading pharmaceutical company revealed its very first quarter results for the current on Tuesday, July 27, after which its share price
gained around three per cent during the trading session
Morepen Laboratories opened on the BSE at Rs 67.85, swinging to an intra day high of Rs 71, and an intra day low of Rs 66.60, throughout the
Shares of Morepen Labs settled 2.62 percent greater at Rs 68.45 each on the BSE
The Delhi-based pharma company's net profits in the Juen quarter stood at Rs 388.31 crore, compared to Rs 258.97 crore in the
corresponding quarter in 2015, marking a growth of 50 percent year-on-year
The company tape-recorded its highest-ever quarterly income development at 50 percent in the April-June quarter, according to a regulatory
filing by the firm to the stock exchanges.Morepen Laboratory's medical gadgets business likewise recorded the highest ever quarterly
income with a growth of 189 per cent on a consecutive basis
The business's domestic service registered a growth of 95 percent to Rs 275.84 crore in the June quarter, driven by the development
contributed by domestic earnings of diagnostics gadgets and the API business.The pharma major consolidated the Russian Direct Mutual Fund or
RDIF - Russia's sovereign wealth fund, for the expansion of the production of Sputnik V vaccine, in a special facility in Himachal
